ClinicalTrials.gg
Active, not recruitingNCT04915755ZESTUpdated Jul 16, 2025Results posted

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

A Phase 3 interventional study of Niraparib and Placebo in Neoplasms, Breast, sponsored by GlaxoSmithKline. Active, not recruiting at 198 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's title name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 163 open to participants now, 264 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Enrollment
355th of 605
40 · median 52
Started
2021
with 49 others
Phase 3
27 of 645
6 open now
Primary completion
2024-06
later than 21 of 263 live
Registered
421st of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 355th largest by enrollment of the 605 interventional ones that give a count, is one of 50 that started in 2021, is one of 27 in phase 3, reaches primary completion later than 21 of the 263 other live ones, and was the 421st registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

163 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast cancer (Independent of hormone receptor [HR] status, including HR positive [+] and TNBC) or tumor BRCA wild type (tBRCAwt) TNBC with molecular disease based on the presence of circulating tumor Deoxyribonucleic acid (ctDNA) following surgery or completion of adjuvant therapy.

03

Conditions studied

  • Neoplasms, Breast

Browse trials for

Keywords

  • Niraparib
  • Breast cancer susceptibility gene
  • Human epidermal growth factor-2 negative (HER2)
  • Breast cancer
  • Triple negative breast cancer (TNBC)
  • Circulating tumor Deoxyribonucleic acid (ctDNA)
04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

This study's enrollment of 40 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage I to III breast cancer with surgical resection of the primary tumor that is confirmed to be either: TNBC, irrespective of BRCA status or HR+/- breast cancer with a known and documented deleterious or suspected deleterious tBRCA mutation.
  • Estrogen receptor (ER) and/or progesterone receptor (PgR) negativity is defined as immunohistochemistry (IHC) nuclear staining less than (\<) 1 percentage (%), or by Allred scoring system where TNBC is defined to be 0 out of 8 or 2 out of 8, or staining in \<1 % of cancer cells.
  • Completed prior standard therapy for curative intent.
  • Participants with HR+ breast cancer must be on a stable regimen of endocrine therapy.
  • Detectable ctDNA as measured by central testing.
  • An specimen of the primary tumor sufficient in quality and quantity for ctDNA assay design and tBRCA and Homologous recombination deficiency (HRD) testing is required.
  • An (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a Poly Adenosine-diphosphate Ribose Polymerase (PARP) inhibitor.
  • Current treatment with a Cyclin-dependent kinase (CDK)4/6 inhibitor or endocrine therapy other than anastrozole, letrozole, exemestane, and tamoxifen with or without ovarian suppression.
  • Participants have any sign of or local recurrence after comprehensive assessment conducted per protocol.
  • Participants have shown no definitive response to preoperative chemotherapy by pathologic, radiographic or clinical evaluation, in cases where preoperative chemotherapy was administered.
  • Participants have inadequately treated or controlled hypertension.
  • Participants have received within 30 days of planned start of study randomization.
  • Participants have a second primary .
  • Exceptions are the following: (a) Adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, Ductal carcinoma in situ (DCIS) of the breast, Stage I Grade 1 endometrial carcinoma. (b) Other solid tumors and lymphomas (without bone marrow involvement) diagnosed >=5 years prior to randomization and treated with no evidence of disease recurrence and for whom no more than 1 was applied.
  • Participant is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and/or for up to 180 days after the last dose of study treatment (except France).
  • Participant is . Participants with splenectomy are allowed. Participants with known (HIV) are allowed if they meet protocol-defined criteria.
  • Participants have a known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort1:Participants with tBRCAmut HER2-breast cancer(Independent of HR status,including HR+andTNBC)

    Eligible participants will receive either Niraparib or Placebo.

    Drug: Niraparib · Drug: Placebo

  • Experimental
    Cohort 2: Participants with tBRCAwt TNBC

    Eligible participants will receive either Niraparib or Placebo.

    Drug: Niraparib · Drug: Placebo

Interventions

  • Niraparib will be administered.

  • DrugPlacebo

    Matching placebo will be administered

07

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Event (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, is a congenital anomaly/birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subsets of AEs. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. AESI is any AE (serious or nonserious) that is of scientific and medical concern specific to niraparib for which ongoing monitoring and rapid communication by the Investigator to the Sponsor is warranted. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to approximately 125 weeks

  2. Number of Participants With TEAEs Leading to Death

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state.Number of participants with TEAEs leading to death were reported.

    Time frame: Up to approximately 125 weeks

  3. Number of Participants With TEAEs Leading to Dose Modifications and Discontinuation of Study Treatment

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. Number of participants with TEAEs leading to dose modifications (reduction and interruption/delay) and permanent discontinuation of study treatment were reported.

    Time frame: Up to approximately 125 weeks

  4. Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status

    Number of participants with ECOG Performance Status was reported and was measured on 6-point grade scale 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead. Data is presented as baseline grade, best case on-therapy, and worst-case on-therapy for the available participants.

    Time frame: Up to approximately 125 weeks

  5. Number of Participants With Worst-Case Post-Baseline (WCPB) Hematology Results Relative to Baseline

    Blood samples were collected for the analysis of hematology parameters. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest non-missing pre-dose value, including those from unscheduled visits.

    Time frame: Up to approximately 125 weeks

  6. Number of Participants With Worst-Case Post-Baseline (WCPB) Clinical Chemistry Results Relative to Baseline

    Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low, changes to normal or no changes from Baseline, and increases to high values have been presented. Baseline is defined as the latest non-missing pre-dose value, including those from unscheduled visits.

    Time frame: Up to approximately 125 weeks

  7. Number of Participants With Worst-Case Post-Baseline (WCPB) Vital Signs Results Relative to Baseline

    The abnormal vital sign ranges are: Pulse Rate (PR): Low \[\<60 beats per minute (bpm)\], Normal (60 bpm to 100 bpm), High (\>100 bpm); Temperature: Low (\<35 degree Celsius (°C)), Normal (35 C and 38 C), High (\>38 C); Systolic Blood Pressure (SBP): Low (\<90 millimeter of mercury (mmHg)), Normal (\>90 mmHg to \<120 mmHg), High (\>120 mmHg); Diastolic Blood Pressure (DBP): Low (\<60 mmHg), Normal (60 mmHg to 79 mmHg), High (\>80 mmHg). Participants were counted in the maximum worst case increase category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category.

    Time frame: Up to approximately 125 weeks

  8. Number of Participants With Use of Concomitant Medications

    Number of participants who used concomitant medications is presented.

    Time frame: Up to approximately 125 weeks

08

Results

Posted Jul 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneNiraparibPlacebo
Started1822
Completed46
Not completed1416
Withdrew: Physician decision32
Withdrew: Withdrawal by subject11
Withdrew: Ongoing for pact32
Withdrew: Other711

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Event (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, is a congenital anomaly/birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subsets of AEs. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. AESI is any AE (serious or nonserious) that is of scientific and medical concern specific to niraparib for which ongoing monitoring and rapid communication by the Investigator to the Sponsor is warranted. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to approximately 125 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Event (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
ParticipantsNiraparibPlacebo
TEAEs1817
SAEs51
AESIs00
PrimaryNumber of Participants With TEAEs Leading to Death

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state.Number of participants with TEAEs leading to death were reported.

Time frame:
Up to approximately 125 weeks
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Death
ParticipantsNiraparibPlacebo
Number of Participants With TEAEs Leading to Death00
PrimaryNumber of Participants With TEAEs Leading to Dose Modifications and Discontinuation of Study Treatment

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. Number of participants with TEAEs leading to dose modifications (reduction and interruption/delay) and permanent discontinuation of study treatment were reported.

Time frame:
Up to approximately 125 weeks
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Dose Modifications and Discontinuation of Study Treatment
ParticipantsNiraparibPlacebo
Dose reduction100
Dose interruption/delay111
Permanent discontinuation of study treatment00
PrimaryNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status

Number of participants with ECOG Performance Status was reported and was measured on 6-point grade scale 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead. Data is presented as baseline grade, best case on-therapy, and worst-case on-therapy for the available participants.

Time frame:
Up to approximately 125 weeks
Reported as:
Count of participants · Participants
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
ParticipantsNiraparibPlacebo
Baseline, Grade 01616
Baseline, Grade 126
Worst Case On-therapy, Grade 079
Worst Case On-therapy, Grade 1911
Worst Case On-therapy, Grade 220
Worst Case On-therapy, Grade 301
Best Case On-therapy, Grade 01717
Best Case On-therapy, Grade 114
PrimaryNumber of Participants With Worst-Case Post-Baseline (WCPB) Hematology Results Relative to Baseline

Blood samples were collected for the analysis of hematology parameters. The summaries of worst-case change from baseline with respect to normal range was analyzed for only those laboratory tests that were not gradable by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest non-missing pre-dose value, including those from unscheduled visits.

Time frame:
Up to approximately 125 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst-Case Post-Baseline (WCPB) Hematology Results Relative to Baseline
ParticipantsNiraparibPlacebo
Basophils, To Low31
Basophils, To Normal or No Change1219
Basophils, To High10
Eosinophils, To Low43
Eosinophils, To Normal or No Change1215
Eosinophils, To High02
Erythrocyte Mean Corpuscular Volume (MCV), To Low11
MCV, To Normal or No Change921
MCV, To High90
Hematocrit, To Low106
Hematocrit, To Normal or No Change815
Hematocrit, To High11
Hemoglobin, To Low96
Hemoglobin, To Normal or No Change916
Hemoglobin, To High00
Leukocytes, To Low132
Leukocytes, To Normal or No Change319
Leukocytes, To High41
Lymphocytes, To Low91
Lymphocytes, To Normal or No Change921
Lymphocytes, To High00
Monocytes, To Low51
Monocytes, To Normal or No Change1017
Monocytes, To High12
Neutrophils, To Low96
Neutrophils, To Normal or No Change814
Neutrophils, To High32
Platelets, To Low80
Platelets, To Normal or No Change721
Platelets, To High41
PrimaryNumber of Participants With Worst-Case Post-Baseline (WCPB) Clinical Chemistry Results Relative to Baseline

Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low, changes to normal or no changes from Baseline, and increases to high values have been presented. Baseline is defined as the latest non-missing pre-dose value, including those from unscheduled visits.

Time frame:
Up to approximately 125 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst-Case Post-Baseline (WCPB) Clinical Chemistry Results Relative to Baseline
ParticipantsNiraparibPlacebo
Alanine aminotransferase (ALT), To Low01
ALT, To Normal or No Change1215
ALT, To High65
Albumin, To Low13
Albumin, To Normal or No Change1518
Albumin, To High20
Alkaline phosphatase (AP), To Low10
AP, To Normal or No Change1316
AP, To High44
Amylase, To Low00
Amylase, To Normal or No Change87
Amylase, To High00
Aspartate aminotransferase (AST), To Low00
AST, To Normal or No Change1218
AST, To High63
Bicarbonate, To Low21
Bicarbonate, To Normal or No Change59
Bicarbonate, To High63
Bilirubin, To Low23
Bilirubin, To Normal or No Change1418
Bilirubin, To High20
Calcium, To Low30
Calcium, To Normal or No Change1218
Calcium, To High33
Carbon Dioxide, To Low00
Carbon Dioxide, To Normal or No Change44
Carbon Dioxide, To High00
Chloride, To Low43
Chloride, To Normal or No Change1114
Chloride, To High34
Creatinine, To Low11
Creatinine, To Normal or No Change1117
Creatinine, To High62
Direct Bilirubin, To Low10
Direct Bilirubin, To Normal or No Change1213
Direct Bilirubin, To High22
Glucose, To Low12
Glucose, To Normal or No Change1113
Glucose, To High76
Lipase, To Low00
Lipase, To Normal or No Change34
Lipase, To High00
Magnesium, To Low11
Magnesium, To Normal or No Change87
Magnesium, To High00
Phosphate, To Low00
Phosphate, To Normal or No Change510
Phosphate, To High20
Potassium, To Low22
Potassium, To Normal or No Change1316
Potassium, To High33
Protein, To Low62
Protein, To Normal or No Change1117
Protein, To High11
Sodium, To Low31
Sodium, To Normal or No Change1419
Sodium, To High11
Urate, To Low31
Urate, To Normal or No Change26
Urate, To High10
Urea, To Low01
Urea, To Normal or No Change1013
Urea, To High51
Urea Nitrogen, To Low01
Urea Nitrogen, To Normal or No Change23
Urea Nitrogen, To High01
PrimaryNumber of Participants With Worst-Case Post-Baseline (WCPB) Vital Signs Results Relative to Baseline

The abnormal vital sign ranges are: Pulse Rate (PR): Low \[\<60 beats per minute (bpm)\], Normal (60 bpm to 100 bpm), High (\>100 bpm); Temperature: Low (\<35 degree Celsius (°C)), Normal (35 C and 38 C), High (\>38 C); Systolic Blood Pressure (SBP): Low (\<90 millimeter of mercury (mmHg)), Normal (\>90 mmHg to \<120 mmHg), High (\>120 mmHg); Diastolic Blood Pressure (DBP): Low (\<60 mmHg), Normal (60 mmHg to 79 mmHg), High (\>80 mmHg). Participants were counted in the maximum worst case increase category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category.

Time frame:
Up to approximately 125 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst-Case Post-Baseline (WCPB) Vital Signs Results Relative to Baseline
ParticipantsNiraparibPlacebo
DBP, To Low00
DBP, To within Range or No Change1322
DBP, To High50
PR, To Low14
PR, To within Range or No Change916
PR, To High82
SBP, To Low00
SBP, To within Range or No Change1221
SBP, To High61
Temperature, To Low00
Temperature, To within Range or No Change1821
Temperature, To High00
PrimaryNumber of Participants With Use of Concomitant Medications

Number of participants who used concomitant medications is presented.

Time frame:
Up to approximately 125 weeks
Reported as:
Count of participants · Participants
Number of Participants With Use of Concomitant Medications
ParticipantsNiraparibPlacebo
Number of Participants With Use of Concomitant Medications1818

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected approximately 125 weeks. The results presented are based on data cut-off date 28 June 2024.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Niraparib0/18 (0%)5/18 (27.8%)18/18 (100%)
Placebo3/22 (13.6%)1/22 (4.5%)17/22 (77.3%)
Most frequent serious events
Most frequent serious events
EventNiraparibPlacebo
AnaemiaBlood and lymphatic system disorders2/180/22
Subendocardial ischaemiaCardiac disorders1/180/22
Macular holeEye disorders1/180/22
PneumothoraxRespiratory, thoracic and mediastinal disorders1/180/22
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/180/22
ArthralgiaMusculoskeletal and connective tissue disorders0/181/22
Pain in extremityMusculoskeletal and connective tissue disorders0/181/22
Most frequent other events
Showing 10 of 127
Most frequent other events
EventNiraparibPlacebo
ConstipationGastrointestinal disorders8/183/22
FatigueGeneral disorders7/187/22
AnaemiaBlood and lymphatic system disorders6/182/22
HypertensionVascular disorders6/180/22
DyspnoeaRespiratory, thoracic and mediastinal disorders5/181/22
DiarrhoeaGastrointestinal disorders2/186/22
NauseaGastrointestinal disorders4/186/22
ArthralgiaMusculoskeletal and connective tissue disorders1/185/22
HeadacheNervous system disorders4/185/22
AstheniaGeneral disorders3/184/22

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)NiraparibPlaceboTotal
Mean58.1 ± 10.0354.3 ± 14.2256.0 ± 12.51
Sex: Female, Male
Sex: Female, Male(Participants)NiraparibPlaceboTotal
Female182240
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)NiraparibPlaceboTotal
White121830
Unknown011
All other races639
09

Study locations

198 sites
  • GSK Investigational Site
    Burbank, California 91505, United States
  • GSK Investigational Site
    Duarte, California 91010, United States
  • GSK Investigational Site
    Palo Alto, California 94304, United States
  • GSK Investigational Site
    San Francisco, California 94158, United States
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
  • GSK Investigational Site
    Highlands Ranch, Colorado 80045, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Skokie, Illinois 60076, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48109, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87106, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    Fargo, North Dakota 58122, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Sioux Falls, South Dakota 57104, United States
  • GSK Investigational Site
    Austin, Texas 78731, United States
  • GSK Investigational Site
    Dallas, Texas 75231, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77024, United States
  • GSK Investigational Site
    San Antonio, Texas 78240, United States
  • GSK Investigational Site
    Tyler, Texas 75702, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
  • GSK Investigational Site
    Everett, Washington 98201, United States
  • GSK Investigational Site
    Buenos Aires, C1017 AAS, Argentina
  • GSK Investigational Site
    Buenos Aires, C1125ABD, Argentina
  • GSK Investigational Site
    Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Capital Federal, C1426ANZ, Argentina
  • GSK Investigational Site
    Cipoletti Rio Negro, R8324CVE, Argentina
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, C1430EGF, Argentina
  • GSK Investigational Site
    Ciudad AutOnoma de Buenos Aire, C1015ABO, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1426AGE, Argentina
  • GSK Investigational Site
    Ciudad de Buenos Aires, C1118AAT, Argentina
  • GSK Investigational Site
    Entre Ríos, 2822, Argentina
  • GSK Investigational Site
    Camperdown, New South Wales 2050, Australia
  • GSK Investigational Site
    Macquarie Park, New South Wales 2109, Australia
  • GSK Investigational Site
    North Sydney, New South Wales 2060, Australia
  • GSK Investigational Site
    Feldkirch, A-6830, Austria
  • GSK Investigational Site
    Innsbruck, 6020, Austria
  • GSK Investigational Site
    Steyr, 4400, Austria
  • GSK Investigational Site
    Vienna, A-1090, Austria
  • GSK Investigational Site
    Brussels, 1070, Belgium
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Charleroi, 6000, Belgium
  • GSK Investigational Site
    Ghent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Belo Horizonte, 30130-100, Brazil
  • GSK Investigational Site
    Florianópolis, 88034-000, Brazil
  • GSK Investigational Site
    Porto Alegre, 90020-090, Brazil
  • GSK Investigational Site
    Porto Alegre, 90610000, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 20560-120, Brazil
  • GSK Investigational Site
    Rio Grande, 95070-560, Brazil
  • GSK Investigational Site
    Salvador, 40170-110, Brazil
  • GSK Investigational Site
    São Paulo, 01317000, Brazil
  • GSK Investigational Site
    São Paulo, 04312903, Brazil
  • GSK Investigational Site
    Vitória, 29043-260, Brazil
  • GSK Investigational Site
    Calgary, Alberta T2N 4N2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Montreal, Quebec H3T 1E2, Canada
  • GSK Investigational Site
    Québec, Quebec G1S 4L8, Canada
  • GSK Investigational Site
    Santiago, 7500653, Chile
  • GSK Investigational Site
    Santiago, 7500836, Chile
  • GSK Investigational Site
    Temuco, 5360000, Chile
  • GSK Investigational Site
    Helsinki, 00180, Finland
  • GSK Investigational Site
    Helsinki, HUS 00029, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Avignon, 84918, France
  • GSK Investigational Site
    Bordeaux, 33076, France
  • GSK Investigational Site
    Caen, 14000, France
  • GSK Investigational Site
    Dijon, 21000, France
  • GSK Investigational Site
    Marseille, 13915, France
  • GSK Investigational Site
    Montpellier, 34070, France
  • GSK Investigational Site
    Pierre-Bénite, 69495, France
  • GSK Investigational Site
    Rouen, 76000, France
  • GSK Investigational Site
    Saint-Cloud, 92210, France
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Cologne, 50935, Germany
  • GSK Investigational Site
    Erlangen, 91054, Germany
  • GSK Investigational Site
    Essen, 45136, Germany
  • GSK Investigational Site
    Mannheim, 68167, Germany
  • GSK Investigational Site
    München, 81377, Germany
  • GSK Investigational Site
    Ulm, 89075, Germany
  • GSK Investigational Site
    Debrecen, 4032, Hungary
  • GSK Investigational Site
    Dublin, 8, Ireland
  • GSK Investigational Site
    Dublin, 9, Ireland
  • GSK Investigational Site
    Beersheba, 84101, Israel
  • GSK Investigational Site
    Haifa, 31096, Israel
  • GSK Investigational Site
    Jerusalem, 91031, Israel
  • GSK Investigational Site
    Jerusalem, 91120, Israel
  • GSK Investigational Site
    Petah Tikva, 49100, Israel
  • GSK Investigational Site
    Rehovot, 76100, Israel
  • GSK Investigational Site
    Tel Aviv, 64239, Israel
  • GSK Investigational Site
    Ancona, 60126, Italy
  • GSK Investigational Site
    Ancona, 62100, Italy
  • GSK Investigational Site
    Bologna, 40138, Italy
  • GSK Investigational Site
    Brindisi, 72100, Italy
  • GSK Investigational Site
    Candiolo to, 10060, Italy
  • GSK Investigational Site
    Catania, 95122, Italy
  • GSK Investigational Site
    Genova, 16132, Italy

Showing the first 100 of 198 sites across 27 countries. Choose a country and city above to see the rest.

10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jun 2024, 36 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2021
First posted
Jun 7, 2021
StartActual
Jun 28, 2021
Primary completionActual
Jun 28, 2024
CompletionEst.
Dec 31, 2025
Results first posted
Jul 16, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04915755
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 7, 2021
Start date
Jun 28, 2021
Primary completion
Jun 28, 2024
Completion
Dec 31, 2025 (estimated)
Results posted
Jul 16, 2025
Last update
Jul 16, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion